List of Excipients in Branded Drug MAXIMUM STRENGTH PEPCID AC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kenvue Brands LLC	MAXIMUM STRENGTH PEPCID AC	famotidine	16837-889	CARNAUBA WAX
Kenvue Brands LLC	MAXIMUM STRENGTH PEPCID AC	famotidine	16837-889	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	MAXIMUM STRENGTH PEPCID AC	famotidine	16837-889	FD&C BLUE NO. 1 ALUMINUM LAKE
Kenvue Brands LLC	MAXIMUM STRENGTH PEPCID AC	famotidine	16837-889	HYPROMELLOSE 2910

Maximum Strength Pepcid AC Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Maximum Strength Pepcid AC is an OTC famotidine 20 mg immediate-release tablet used for the prevention and relief of heartburn. Its commercial position depends on brand recognition, rapid symptom relief, retail distribution, and price rather than active-ingredient exclusivity. The core excipient system is conventional and offers limited defensibility, but it creates opportunities for lower-cost manufacturing, alternative dosage forms, improved swallowability, clean-label positioning, and private-label competition.

What is Maximum Strength Pepcid AC?

Maximum Strength Pepcid AC contains famotidine 20 mg per tablet. In the U.S., the product is marketed as an OTC histamine-2 receptor antagonist for heartburn prevention and relief. The label permits adults and children 12 years and older to take one tablet before eating or drinking food likely to cause heartburn, with a maximum of two tablets daily and a maximum treatment period of 14 days without medical advice. [1]

Product attribute	Maximum Strength Pepcid AC
Active ingredient	Famotidine
Strength	20 mg
Dosage form	Film-coated oral tablet
Market	U.S. OTC
Therapeutic category	Heartburn relief; H2-receptor antagonist
Primary manufacturer/labeler	Johnson & Johnson Consumer Inc. product lineage; current commercial ownership and labeler should be confirmed against the live package and DailyMed record
FDA pathway	OTC monograph pathway for famotidine heartburn products
Prescription status	Famotidine also remains available as a generic prescription product
Orange Book status	Pepcid AC OTC products generally are not Orange Book-listed prescription products
Core commercial competitors	Generic famotidine 20 mg, store-brand famotidine, omeprazole products, esomeprazole products, calcium carbonate antacids, and alginate-based products

The product is an immediate-release tablet rather than an extended-release or enteric-coated system. Its excipient requirements are therefore relatively straightforward: tablet strength, rapid disintegration, acceptable dissolution, coating integrity, stability, and consumer acceptability.

What excipients are used in Maximum Strength Pepcid AC?

The U.S. product labeling identifies conventional tablet and film-coating excipients, including microcrystalline cellulose, pregelatinized starch, magnesium stearate, hypromellose, hydroxypropyl cellulose, titanium dioxide, and carnauba wax. Exact inactive-ingredient declarations can change by manufacturing site, product presentation, or labeling update. [1]

Excipient category	Likely function in the tablet	Commercial relevance
Microcrystalline cellulose	Filler and dry-binding agent	Supports direct compression and tablet strength
Pregelatinized starch	Binder, filler, and disintegration aid	Improves compaction and breakup after ingestion
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction
Hypromellose	Film-coating polymer	Provides color, surface protection, and swallowability
Hydroxypropyl cellulose	Film-forming or coating-support polymer	Supports coating performance and adhesion
Titanium dioxide	Opacifier and pigment	Produces a uniform, recognizable tablet appearance
Carnauba wax	Gloss and surface-finishing agent	Supports polished appearance and brand identification

This system is optimized for an established, high-volume tablet rather than for novel delivery. It uses familiar compendial materials, which reduces formulation and supply-chain risk. The principal technical challenge is not achieving therapeutic release. It is maintaining consistent physical quality at low cost while preserving the recognizable Pepcid tablet appearance.

How does the excipient strategy support product performance?

The formulation strategy has four operating objectives.

1. Rapid immediate-release performance

Famotidine is intended to dissolve and become available promptly after oral administration. The formulation should avoid excessive hydrophobic lubrication, over-compression, or a dense coating that delays disintegration. Magnesium stearate level and blending time require control because over-lubrication can reduce tablet wetting and slow dissolution.

A generic developer can improve process robustness through:

• tighter magnesium stearate concentration controls;
• shorter lubricant blending windows;
• optimized pregelatinized starch levels;
• controlled compression force;
• disintegration testing alongside dissolution testing;
• excipient particle-size controls.

2. Mechanical strength

The tablet must withstand coating, packaging, transportation, and consumer handling. Microcrystalline cellulose and pregelatinized starch provide a conventional route to hardness without requiring a complex granulation process.

A direct-compression formula may reduce manufacturing cost. A roller-compacted formula may be preferable if powder flow, segregation, or dose uniformity becomes problematic. Because famotidine is present at a relatively small mass fraction compared with the full tablet, blend uniformity and segregation controls remain important.

3. Brand-recognizable appearance

Color and coating are commercial rather than therapeutic features. The film coat allows the manufacturer to control tablet color, gloss, opacity, and surface texture. These attributes influence consumer recognition and can help distinguish the branded product from white or differently shaped store-brand tablets.

A substitute product can use a similar appearance, but copying trade dress or confusingly similar branding creates separate trademark and product-presentation risks. Excipient selection alone does not resolve those issues.

4. Stability and packaging compatibility

Famotidine products require control of moisture exposure, coating integrity, and packaging performance. The commercial formulation should be evaluated with:

• high-density polyethylene bottles;
• induction seals;
• desiccant configurations;
• blister packaging;
• unit-dose packaging;
• accelerated and long-term stability conditions;
• tablet friability after transport simulation.

Moisture-barrier packaging may be more commercially valuable than a novel excipient. It can protect tablet appearance and dissolution without materially changing the formulation.

What excipient substitutions could improve a generic or private-label product?

The most practical substitution opportunities are cost, manufacturability, label simplicity, and consumer differentiation.

Objective	Potential excipient strategy	Likely benefit	Key risk
Lower manufacturing cost	Replace multiple binders with a co-processed filler-binder	Fewer material inputs and simpler processing	New dissolution and compression profile
Improve direct compression	Use spray-dried or silicified microcrystalline cellulose	Better flow and tablet uniformity	Higher excipient cost
Reduce tablet size	Use higher-functionality fillers and optimized compression	Easier swallowing	Hardness, friability, and dissolution changes
Improve disintegration	Add crospovidone, croscarmellose sodium, or sodium starch glycolate	Faster tablet breakup	Possible swelling, friability, or blend segregation
Clean-label positioning	Use starch-based or mineral-based alternatives where feasible	Supports retailer or consumer claims	Fewer formulation options and possible performance loss
Remove titanium dioxide	Use alternative pigments or opaque coating systems	Addresses retailer and consumer preferences	Color consistency and coating opacity
Improve coating efficiency	Use optimized hypromellose-based premix	Lower coating time and batch variability	Supplier dependence
Reduce lubricant sensitivity	Use alternative lubricant systems or lower magnesium stearate loading	Better dissolution robustness	Ejection and tooling problems
Improve swallowability	Use lower-friction film coatings and tablet-edge optimization	Better consumer experience	Requires tablet redesign and stability work

A developer should not assume that a familiar excipient substitution is automatically equivalent. A change in disintegrant, lubricant, coating polymer, or filler can affect dissolution, hardness, friability, stability, content uniformity, and bioequivalence risk.

What dosage-form opportunities exist beyond the standard tablet?

Chewable famotidine

A chewable 20 mg product could target consumers who have difficulty swallowing tablets. The major excipient issues would be taste masking, mouthfeel, tablet erosion, and mechanical strength. Famotidine taste control may require flavors, sweeteners, high-intensity sweeteners, polymeric taste-masking systems, or coated drug particles.

Commercial value is potentially high because a chewable product could occupy a different consumer-use occasion. The tradeoff is a more complex formulation and a higher risk of unpleasant aftertaste.

Orally disintegrating tablet

An orally disintegrating tablet could target rapid administration without water. It would require low-moisture processing, rapid disintegration, acceptable mouthfeel, and strong packaging protection. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavor systems are common development tools for this category.

An ODT would be more differentiated than a conventional generic tablet, but its regulatory pathway and manufacturing economics would be more demanding.

Liquid or suspension

A famotidine liquid could target pediatric or swallowing-limited populations, subject to the applicable OTC labeling and regulatory requirements. Development would require attention to preservative efficacy, pH, sedimentation, viscosity, dosing-device accuracy, and chemical stability.

Liquid products have higher packaging and supply-chain costs than tablets. They may also create more stability and microbial-control obligations.

Dual-action heartburn products

Combination products pairing famotidine with an antacid may offer faster initial neutralization and longer acid suppression. Calcium carbonate, magnesium hydroxide, aluminum hydroxide, or other antacid systems introduce compatibility, taste, dose-volume, and labeling issues.

A combination product cannot rely solely on the monograph status of famotidine. The complete active-ingredient combination, dosage form, labeling, and claims must comply with the applicable FDA requirements. [2]

What FDA regulatory issues affect excipient commercialization?

Famotidine OTC products are regulated under the FDA’s OTC monograph framework when the formulation, active ingredient, dosage, labeling, and claims fit the applicable conditions. The FDA’s final monograph for OTC heartburn treatment identifies famotidine as a permitted active ingredient at specified dosages and directions. [2]

Excipient changes can create different regulatory consequences:

Change	Typical regulatory implication
Change in filler, binder, or lubricant in an otherwise equivalent tablet	May be handled within an abbreviated or monograph-based product framework, subject to required quality data
New dosage form	May require a different regulatory assessment and supporting data
New combination active ingredients	Requires review against combination-product requirements
New therapeutic claim	May fall outside OTC monograph conditions
New pediatric use	Requires appropriate safety, labeling, and regulatory support
New flavor, color, or coating	Requires inactive-ingredient, quality, and labeling evaluation
Novel excipient	Creates additional safety and regulatory burden
Same active ingredient but materially different release profile	May create equivalence and product-performance concerns

A formulation strategy based on well-established excipients is commercially preferable because it reduces regulatory friction. A novel excipient is unlikely to create adequate value in a low-price OTC category unless it solves a clear problem such as taste masking, rapid disintegration, moisture stability, or dose reduction.

What patents protect Maximum Strength Pepcid AC?

The original famotidine composition and use patents are expired or commercially exhausted in the United States. Maximum Strength Pepcid AC does not depend on an active ingredient patent for market exclusivity. Generic famotidine is widely available, and the branded OTC product is exposed to store-brand substitution.

Pepcid AC is generally not an Orange Book-listed prescription product because the OTC product is not approved and listed in the same manner as an NDA prescription medicine. Orange Book patent certifications and Paragraph IV litigation are therefore not the primary competitive framework for the product. [3]

Potentially relevant IP categories include:

• formulation patents covering a specific chewable, ODT, liquid, or combination product;
• process patents covering granulation, coating, or low-moisture manufacturing;
• packaging patents covering unit-dose or moisture-control systems;
• design and trade-dress rights covering tablet appearance and packaging;
• trademarks covering Pepcid and related brand identifiers;
• supplier agreements governing proprietary co-processed excipients or coating systems.

A new excipient combination could support patent protection only if it produces a non-obvious technical result. A routine substitution of microcrystalline cellulose, starch, magnesium stearate, or hypromellose is unlikely to create a strong composition-of-matter position by itself.

When does Maximum Strength Pepcid AC lose exclusivity?

Maximum Strength Pepcid AC has no meaningful remaining U.S. data or market exclusivity comparable to a newly approved prescription drug. The relevant commercial event occurred when generic and store-brand famotidine products entered the market.

Exclusivity category	Current commercial assessment
Active-ingredient patent	Expired or no longer commercially blocking
Prescription drug exclusivity	Expired
OTC monograph protection	No brand-specific exclusivity
Orange Book-listed patent protection	Generally not applicable to the OTC product
Trademark protection	May remain active for brand names and logos
Formulation or packaging IP	Product-specific and requires claim-by-claim review
Retail exclusivity	Contractual and channel-specific, not statutory

The brand retains value through consumer awareness, retailer placement, perceived reliability, and packaging. That value is vulnerable to lower-priced private-label famotidine.

What commercial opportunities exist for excipient suppliers and manufacturers?

Private-label famotidine

The largest opportunity is a low-cost 20 mg tablet that matches the performance of branded Pepcid AC. Excipient suppliers can compete through:

• direct-compression systems;
• high-flow filler-binders;
• pregelatinized starch grades;
• low-dose blend-uniformity solutions;
• film-coating premixes;
• moisture-barrier packaging;
• reduced manufacturing cycle times.

Retailers may prioritize supply reliability, cost per tablet, and visual differentiation over novel clinical features.

Premium OTC line extensions

A premium product could use a smaller tablet, easier-swallow coating, chewable format, ODT presentation, or dual-action formulation. The value proposition must be clear because famotidine is already inexpensive and familiar.

Clean-label and retailer-restricted formulations

Some retailers restrict titanium dioxide, artificial colors, certain excipients, or animal-derived materials. A reformulated product could target those procurement requirements. The commercial benefit depends on maintaining tablet appearance, stability, and dissolution while avoiding a meaningful cost increase.

Contract manufacturing

Manufacturers with high-throughput coating, blistering, and bottle-filling capacity can offer turnkey famotidine products to private-label customers. Manufacturing barriers are operational rather than patent-based. They include controlled blending, validated dissolution, coating uniformity, packaging-line flexibility, and regulatory documentation.

Geographic expansion

Famotidine is marketed globally, but permitted OTC strengths, indications, labeling, and dosage forms differ by jurisdiction. A formulation developed for the U.S. cannot be assumed to qualify in the European Union, Canada, Japan, or emerging markets without local regulatory assessment.

Geographic opportunities are strongest where:

• H2 blockers remain widely used;
• pharmacy and supermarket OTC channels are expanding;
• private-label penetration is limited;
• local manufacturers lack efficient coated-tablet capacity;
• consumers prefer lower-cost branded generics.

How strong is the Pepcid AC patent estate?

The patent estate is weak as a barrier to generic famotidine tablets and stronger as a brand-protection platform.

IP area	Strength against generic tablet entry	Business assessment
Famotidine active ingredient	Low	Generic API and finished products are established
Conventional 20 mg tablet formulation	Low	Standard excipients are readily substitutable
Pepcid trademark	Medium to high	Supports brand recognition but does not block generic entry
Tablet appearance and packaging	Medium	Can limit confusing imitation, not lawful competition
Novel chewable or ODT formulation	Potentially medium	Depends on claims, disclosure, and technical effect
Combination product	Potentially medium	Depends on formulation, claims, and regulatory status
Manufacturing process	Low to medium	Usually difficult to enforce against an independent process
Retail distribution	Medium	Shelf placement and contracts can delay substitution

The strongest commercial defense is brand equity combined with retail execution. The strongest product-development opportunity is a differentiated dosage form, not a minor change to the standard tablet excipient list.

What generic launch risks exist?

A generic or private-label developer faces five principal risks:

1. The reformulated product may fail dissolution or disintegration targets.
2. Coating or color changes may reduce consumer recognition.
3. A cost-saving excipient may create supply or compendial variability.
4. A new dosage form may trigger more extensive regulatory work than expected.
5. Pricing may fall faster than the manufacturer can recover development and validation costs.

Paragraph IV litigation is not the normal entry mechanism for an OTC monograph famotidine tablet. A company entering with a conventional monograph-compliant product is more likely to compete through regulatory compliance, manufacturing scale, retail contracting, trademark clearance, and price.

Key Takeaways

• Maximum Strength Pepcid AC is a famotidine 20 mg immediate-release OTC tablet.
• Its excipient system is conventional: filler-binders, pregelatinized starch, magnesium stearate, film-coating polymers, pigments, and wax.
• The active ingredient and conventional tablet formulation do not provide a strong current exclusivity barrier.
• Orange Book listing and Paragraph IV litigation are generally not central to this OTC product.
• The largest formulation opportunities are chewable tablets, ODTs, liquids, smaller tablets, clean-label versions, and dual-action combinations.
• The most practical excipient opportunities involve direct compression, coating efficiency, moisture control, rapid disintegration, and taste masking.
• Commercial competition is driven by brand equity, retail access, manufacturing cost, and consumer convenience.
• New excipient patents are more plausible for differentiated dosage forms or demonstrable technical effects than for routine ingredient substitutions.

FAQs

Can a generic manufacturer use the same excipients as Maximum Strength Pepcid AC?

Yes. Individual excipients are generally not proprietary. A generic manufacturer can use the same materials if the finished product meets applicable quality, performance, labeling, and regulatory requirements.

Is titanium dioxide necessary in a famotidine tablet?

No. Titanium dioxide is primarily a coating opacifier and color-support ingredient. It can be replaced or removed, but the alternative coating system must maintain appearance, stability, uniformity, and consumer acceptability.

Is a famotidine ODT likely to be more profitable than a standard tablet?

It can support a premium price, but development and manufacturing costs are higher. Profitability depends on whether convenience and differentiation offset lower volume, more complex packaging, and additional formulation work.

Can a private-label product copy Pepcid AC’s tablet color and shape?

A company can develop a therapeutically equivalent product, but it must avoid trademark infringement, trade-dress infringement, and consumer confusion. Similarity in color or shape should be assessed with the complete product presentation, including packaging and labeling.

What is the best excipient opportunity for low-cost famotidine manufacturing?

A robust direct-compression platform using a high-functionality filler-binder, controlled starch disintegration, optimized lubrication, and an efficient film-coating premix is the most practical opportunity for reducing cost while preserving tablet performance.

References

1. National Library of Medicine. (n.d.). DailyMed: Pepcid AC Maximum Strength, famotidine tablet, film coated. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). Over-the-counter monograph M012: Heartburn relief. FDA.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.